000 01466 a2200433 4500
005 20250518004825.0
264 0 _c20190204
008 201902s 0 0 eng d
022 _a2052-1707
024 7 _a10.1002/prp2.436
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLi, Yan
245 0 0 _aPharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects.
_h[electronic resource]
260 _bPharmacology research & perspectives
_c12 2018
300 _ae00436 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase I; Journal Article
650 0 4 _aAdult
650 0 4 _aAminopyridines
_xadministration & dosage
650 0 4 _aAntineoplastic Agents
_xadministration & dosage
650 0 4 _aArea Under Curve
650 0 4 _aAsian People
650 0 4 _aHealthy Volunteers
650 0 4 _aHumans
650 0 4 _aIsocitrate Dehydrogenase
_xantagonists & inhibitors
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aNeoplasms
_xdrug therapy
650 0 4 _aTriazines
_xadministration & dosage
650 0 4 _aWhite People
650 0 4 _aYoung Adult
700 1 _aLiu, Liangang
700 1 _aGomez, Diana
700 1 _aChen, Jian
700 1 _aTong, Zeen
700 1 _aPalmisano, Maria
700 1 _aZhou, Simon
773 0 _tPharmacology research & perspectives
_gvol. 6
_gno. 6
_gp. e00436
856 4 0 _uhttps://doi.org/10.1002/prp2.436
_zAvailable from publisher's website
999 _c29003120
_d29003120